Joanna Nikitorowicz-Buniak

Joanna Nikitorowicz-Buniak

Auto-generated profile, based on publicly available information

Joanna Nikitorowicz-Buniak

Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLesley-Ann Martin
Lesley-Ann Martin
RRRicardo Ribas
Ricardo Ribas
NSNikiana Simigdala
Nikiana Simigdala
ESEugene Schuster
Eugene Schuster
SPSunil Pancholi
Sunil Pancholi
MDMitch Dowsett
Mitch Dowsett
Resistance to endocrine therapy remains a major clinical problem in breast cancer. Genetic studies highlight the potential role of estrogen receptor-α (ESR1) mutations, which show increased prevalence in the metastatic, endocrine-resistant setting. No naturally occurring ESR1 mutations have been reported in in vitro models of BC either before or after the acquisition of endocrine resistance making functional consequences difficult to study. We report the first discovery of naturally occurring ESR1 Y537C and ESR1 Y537S mutations in MCF7 and SUM44 ESR1-positive cell lines after acquisition of resistance to long-term-estrogen-deprivation (LTED) and subsequent resistance to fulvestrant (ICIR). Mutations were enriched with time, impacted on ESR1 binding to the genome and altered the ESR1 interactome. The results highlight the importance and functional consequence of these mutations and provide an important resource for studying endocrine resistance.

8 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
XSXu Shiwen
Xu Shiwen
RSRichard Stratton
Richard Stratton
JNJoanna Nikitorowicz-Buniak
Joanna Nikitorowicz-Buniak
BABahja Ahmed-Abdi
Bahja Ahmed-Abdi
MPMarkella Ponticos
Markella Ponticos
BSBarbara D. Smith
Barbara D. Smith
In scleroderma (systemic sclerosis, SSc), persistent activation of myofibroblast leads to severe skin and organ fibrosis resistant to therapy. Increased mechanical stiffness in the involved fibrotic tissues is a hallmark clinical feature and a cause of disabling symptoms. Myocardin Related Transcription Factor-A (MRTF-A) is a transcriptional co-activator that is sequestered in the cytoplasm and translocates to the nucleus under mechanical stress or growth factor stimulation. Our objective was to determine if MRTF-A is activated in the disease microenvironment to produce more extracellular matrix in progressive SSc. Immunohistochemistry studies demonstrate that nuclear translocation of MRTF-A in scleroderma tissues occurs in keratinocytes, endothelial cells, infiltrating inflammatory cells, and dermal fibroblasts, consistent with enhanced signaling in multiple cell lineages exposed to the stiff extracellular matrix. Inhibition of MRTF-A nuclear translocation or knockdown of MRTF-A synthesis abolishes the SSc myofibroblast enhanced basal contractility and synthesis of type I collagen and inhibits the matricellular profibrotic protein, connective tissue growth factor (CCN2/CTGF). In MRTF-A null mice, basal skin and lung stiffness was abnormally reduced and associated with altered fibrillar collagen. MRTF-A has a role in SSc fibrosis acting as a central regulator linking mechanical cues to adverse remodeling of the extracellular matrix.

1 November 2014 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
JNJoanna Nikitorowicz-Buniak
Joanna Nikitorowicz-Buniak
XSXu Shiwen
Xu Shiwen
CDChristopher P. Denton
Christopher P. Denton
DADavid Abraham
David Abraham
RSRichard Stratton
Richard Stratton

28 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JNJoanna Nikitorowicz-Buniak
Joanna Nikitorowicz-Buniak
CDChristopher P. Denton
Christopher P. Denton
DADavid Abraham
David Abraham
RSRichard Stratton
Richard Stratton
The origin of myofibroblasts in fibrotic conditions remains unknown and in systemic sclerosis (SSc) it has been proposed that activation of local fibroblasts, trans-differentiation of perivascular or vascular cells, recruitment of fibrocyte progenitors, or epithelial to mesenchymal transition (EMT) could be contributing. Data from our laboratory indicate that the epidermis in scleroderma is activated with the keratinocytes exhibiting a phenotype normally associated with tissue repair, including phosphorylation profiles indicative of TGFβ signaling. Since TGFβ is a known inducer of EMT, we investigated if there is evidence of this process in the SSc epidermis. In order to validate antibodies and primers, EMT was modeled in HaCaT cells cultured in the presence of TGFβ1. Skin sections were stained with phosho-SMAD2/3, as well as with epithelial and mesenchymal markers. Moreover, mRNA levels of transcription factors associated with EMT were studied in epidermal blister sheets. We observed critical changes in the scleroderma epidermis; showing significantly increased nuclear translocation of phosphorylated Smad2/3, consistent with active TGFβ signaling in SSc keratinocytes. While profound EMT could be induced in keratinocytes in vitro with the appearance of SNAI1/2 and FSP-1, and an accompanying loss of E-cadherin, in the scleroderma skin active TGFβ signaling was accompanied by only partial EMT-like changes characterised by induction of SNAI1 alone and with no loss of E-cadherin. Together, our findings support a model of altered differentiation and TGFβ dependent activation of scleroderma epithelial cells leading to a partially evoked EMT like process in the fibrotic skin.

1 December 2012 in Ticks and Tick-borne Diseases
Verified
Journal Article
Closed access
VPVera Pader
Vera Pader
JBJoanna Nikitorowicz Buniak
Joanna Nikitorowicz Buniak
AAAlemseged Abdissa
Alemseged Abdissa
HAHaileeysus Adamu
Haileeysus Adamu
TFTadele Tolosa Fulasa
Tadele Tolosa Fulasa
SCSally J. Cutler
Sally J. Cutler

16 June 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SGStephanie K. Guest
Stephanie K. Guest
RRRicardo Ribas
Ricardo Ribas
SPSunil Pancholi
Sunil Pancholi
JNJoanna Nikitorowicz-Buniak
Joanna Nikitorowicz-Buniak
NSNikiana Simigdala
Nikiana Simigdala
LMLesley-Ann Martin
Lesley-Ann Martin
Despite the effectiveness of endocrine therapies in estrogen receptor positive (ER+) breast cancer, approximately 40% of patients relapse. Previously, we identified the Focal-adhesion kinase canonical pathway as a major contributor of resistance to estrogen deprivation and cellular-sarcoma kinase (c-src) as a dominant gene in this pathway. Dasatinib, a pan-src inhibitor, has recently been used in clinical trials to treat ER+ patients but has shown mixed success. In the following study, using isogenic cell line models, we provide a potential explanation for these findings and suggest a sub-group that may benefit. A panel of isogenic cell lines modelling resistance to aromatase inhibitors (LTED) and tamoxifen (TAMR) were assessed for response to dasatinib ± endocrine therapy. Dasatinib caused a dose-dependent decrease in proliferation in MCF7-TAMR cells and resensitized them to tamoxifen and fulvestrant but not in HCC1428-TAMR. In contrast, in estrogen-deprived conditions, dasatinib increased the proliferation rate of parental-MCF7 cells and had no effect on MCF7-LTED or HCC1428-LTED. Treatment with dasatinib caused a decrease in src-phosphorylation and inhibition of downstream pathways, including AKT and ERK1/2 in all cell lines tested, but only the MCF7-TAMR showed a concomitant decrease in markers of cell cycle progression. Inhibition of src also caused a significant decrease in cell migration in both MCF7-LTED and MCF7-TAMR cells. Finally, we showed that, in MCF7-TAMR cells, in contrast to tamoxifen sensitive cell lines, ER is expressed throughout the cell rather than being restricted to the nucleus and that treatment with dasatinib resulted in nuclear shuttling of ER, which was associated with an increase in ER-mediated transcription. These data suggest that src has differential effects in endocrine-resistant cell lines, particularly in tamoxifen resistant models, with low ER genomic activity, providing further evidence of the importance of patient selection for clinical trials testing dasatinib utility in ER+ breast cancer.